Search research articles
Contact Us
Filters
Showing results (31-40 of 54) with videos related to
Page
of 6
Sort By:
BMJ Global Health
|
October 21, 2020
Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries
Jessica Ochalek, Kaja Abbas, Karl Claxton, et al.
International Journal of Environmental Research and Public Health
|
November 8, 2018
Economic Evaluation of Environmental Interventions: Reflections on Methodological Challenges and Developments
Laura Bojke, Laetitia Schmitt, James Lomas, et al.
Health Economics
|
January 16, 2024
Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required
Beth Woods, James Lomas, Mark Sculpher, et al.
Journal of the Royal Statistical Society. Series A, (Statistics in Society)
|
October 25, 2016
A quasi-Monte-Carlo comparison of parametric and semiparametric regression methods for heavy-tailed and non-normal data: an application to healthcare costs
Andrew M Jones, James Lomas, Peter T Moore, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 24, 2020
Cured Today, Ill Tomorrow: A Method for Including Future Unrelated Medical Costs in Economic Evaluation in England and Wales
Meg Perry-Duxbury, Miqdad Asaria, James Lomas, et al.
Health Economics
|
March 19, 2025
Does Publicly-Funded Adult Social Care Impact Informal and Unpaid Carers' Quality of Life in England?
Francesco Longo, Karl Claxton, Andrea Salas-Ortiz, et al.
Lancet (London, England)
|
December 15, 2024
Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000-20: a retrospective analysis
Huseyin Naci, Peter Murphy, Beth Woods, et al.
Pharmacoeconomics
|
August 29, 2020
Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach
Jessica Ochalek, Haiyin Wang, Yuanyuan Gu, et al.
Lancet (London, England)
|
June 28, 2025
Population health impact of NICE-recommended new drugs - Authors' reply
Huseyin Naci, Peter Murphy, Beth Woods, et al.
Pharmacoeconomics - Open
|
April 4, 2019
Correction to: Which Costs Matter? Costs Included in Economic Evaluation and their Impact on Decision Uncertainty for Stable Coronary Artery Disease
James Lomas, Miqdad Asaria, Laura Bojke, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 54) with videos related to
Sort By:
Page
of 6
BMJ Global Health
|
October 21, 2020
Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries
Jessica Ochalek, Kaja Abbas, Karl Claxton, et al.
International Journal of Environmental Research and Public Health
|
November 8, 2018
Economic Evaluation of Environmental Interventions: Reflections on Methodological Challenges and Developments
Laura Bojke, Laetitia Schmitt, James Lomas, et al.
Health Economics
|
January 16, 2024
Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required
Beth Woods, James Lomas, Mark Sculpher, et al.
Journal of the Royal Statistical Society. Series A, (Statistics in Society)
|
October 25, 2016
A quasi-Monte-Carlo comparison of parametric and semiparametric regression methods for heavy-tailed and non-normal data: an application to healthcare costs
Andrew M Jones, James Lomas, Peter T Moore, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 24, 2020
Cured Today, Ill Tomorrow: A Method for Including Future Unrelated Medical Costs in Economic Evaluation in England and Wales
Meg Perry-Duxbury, Miqdad Asaria, James Lomas, et al.
Health Economics
|
March 19, 2025
Does Publicly-Funded Adult Social Care Impact Informal and Unpaid Carers' Quality of Life in England?
Francesco Longo, Karl Claxton, Andrea Salas-Ortiz, et al.
Lancet (London, England)
|
December 15, 2024
Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000-20: a retrospective analysis
Huseyin Naci, Peter Murphy, Beth Woods, et al.
Pharmacoeconomics
|
August 29, 2020
Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach
Jessica Ochalek, Haiyin Wang, Yuanyuan Gu, et al.
Lancet (London, England)
|
June 28, 2025
Population health impact of NICE-recommended new drugs - Authors' reply
Huseyin Naci, Peter Murphy, Beth Woods, et al.
Pharmacoeconomics - Open
|
April 4, 2019
Correction to: Which Costs Matter? Costs Included in Economic Evaluation and their Impact on Decision Uncertainty for Stable Coronary Artery Disease
James Lomas, Miqdad Asaria, Laura Bojke, et al.
Page
of 6